Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia

Anemia, Aplastic Clinical Trial

Official title:

Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia, Using Matched Unrelated Donors and Mismatched Related Donors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00578266
• Other study ID #: 06-006216
• Status: Completed
• Phase: Phase 1
• First received: December 17, 2007
• Last updated: March 23, 2017
• Start date: February 2007
• Est. completion date: August 16, 2016

Study information

• Verified date: March 2017
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

For patients with severe aplastic anemia (SAA) who have failed to respond to immunosuppressive therapy and lack an HLA identical family member, our objectives are to make an initial assessment of the safety and efficacy of allogenic stem cell transplantation from either a matched unrelated donor or a mismatched reacted donor using the conditioning regimen of Cytoxan, reduced total body irradiation (TBI) and Campath IH. The principle measures of safety and efficacy will be :

1. Patient survival probability at 100 days, 1 year and 2 years.

2. Incidence of graft versus host disease (GVHD), as well as incidence of acute GVHD and chronic GVHD within 6 months and 2 years.

3. Engraftment at 6 months, 1 year and 2 years

Description:

The objective of this trial is to make an initial assessment for this new treatment regimen and to show it is equal or superior to the current standard practice. With this initial assessment be hope to gain information suggesting further study of this regimen or discontinuation of this regimen before exposing large numbers of patients to this new treatment option. We also will gain experience with this new regimen giving insights as to possible modifications in dosing and monitoring and selection of patients for future treatment in case of positive results. For this initial study we plan to enroll up to 24 patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 8
• Est. completion date: August 16, 2016
• Est. primary completion date: August 16, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 60 Years

Eligibility

Inclusion Criteria:

• Diagnosis of SAA based on bone marrow aspirate and biopsy results. Failure to respond to immunosuppressive therapy and/or lack of an HLA identical family member.

• A 10/10 or 9/10 HLA matched unrelated donor or a 9/10 matched related donor available after high resolution typing.

Exclusion Criteria:

• Patients with Aplastic anemia and active infection must be treated to maximally resolve this problem before beginning the conditioning regimen.

• HIV seropositive patients

• Patients who have clonal cytogenetic abnormalities or a myelodysplastic syndrome.

• Patient greater than 60 years of age.

• Women who are pregnant or nursing.

• Patients with active hepatitis

• Patients with severe cardiac dysfunction defined as shortening fraction <25%.

• Patients with severe renal dysfunction defined as creatinine clearance <40ml/mim/1.73m2.

• Patient with severe pulmonary dysfunction with FEV1, FVC and DLCO 40% of predicted or 3 SD below normal.

Related Conditions & MeSH terms

• Anemia
• Anemia, Aplastic

Intervention

Drug:
• Cyclophosphamide,Campath IH and TBI
DAY 5 TREATMENT 6 5 CYTOXAN 50 mg/kg WITH MESNA 5 CYTOXAN 50 mg/kg WITH MESNA; 4 CYTOXAN 50 mg/kgWITH MESNA; CAMPATH 3-10 mg 3 CYTOXAN 50 mg/kg WITH MESNA; CAMPATH; 2 TBI; CAMPATH; TACROLIMUS 1 TBI (second fraction); CAMPATH (am) 0 STEM CELL INFUSION (pm)

Locations

Country	Name	City	State
United States	Mayo Clinic	Rochester	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	1. Engraftment at 6 months, 1 year and 2 years 2.Incidence of graft versus host disease (GVHD), as well as incidence of acute GVHD and chronic GVHD within 6 months and 2 years		2 years
Secondary	Patient survival probability at 100 days, 1 year and 2 years.		2 years